Dr Cruz speaks with ecancer at ESMO 2016 about trials for lurbinectedin in patients for whom PARP inhibition is no longer and option.

She describes the mechanisms by which resistance to other medications can be subverted by lurbinectedin, and reports its suitability even for tumours with resistance to standard therapy cisplatin.

Lurbinectedin is discussed further by Dr Judith Balmaña, who spoke with ecancer here.